Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($2.50) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share.
BCAX has been the subject of several other reports. Stifel Nicolaus assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price target for the company. HC Wainwright assumed coverage on Bicara Therapeutics in a report on Friday, December 6th. They set a "buy" rating and a $42.00 target price for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Morgan Stanley started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 price objective for the company. Finally, Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a "buy" rating and a $48.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics presently has an average rating of "Buy" and an average target price of $43.00.
View Our Latest Stock Analysis on Bicara Therapeutics
Bicara Therapeutics Stock Performance
Shares of BCAX stock traded up $0.05 during trading hours on Thursday, hitting $11.97. The company had a trading volume of 277,953 shares, compared to its average volume of 381,654. Bicara Therapeutics has a fifty-two week low of $11.51 and a fifty-two week high of $28.09. The business's fifty day moving average is $17.46.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14).
Hedge Funds Weigh In On Bicara Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $147,000. Barclays PLC purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $255,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $358,000. Geode Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter worth $1,239,000. Finally, Jane Street Group LLC acquired a new position in shares of Bicara Therapeutics during the third quarter worth $309,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Recommended Stories
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
